IL316872A - Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists - Google Patents

Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Info

Publication number
IL316872A
IL316872A IL316872A IL31687224A IL316872A IL 316872 A IL316872 A IL 316872A IL 316872 A IL316872 A IL 316872A IL 31687224 A IL31687224 A IL 31687224A IL 316872 A IL316872 A IL 316872A
Authority
IL
Israel
Prior art keywords
interleukin
antagonists
methods
selectively treating
treating tendinopathy
Prior art date
Application number
IL316872A
Other languages
Hebrew (he)
Inventor
Gerard Bruin
Shea Carter
Frank Kolbinger
Neal Millar
Iain Mcinnes
Matthias Schieker
Eckhard Weber
Original Assignee
Novartis Ag
Gerard Bruin
Shea Carter
Frank Kolbinger
Neal Millar
Iain Mcinnes
Matthias Schieker
Eckhard Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Gerard Bruin, Shea Carter, Frank Kolbinger, Neal Millar, Iain Mcinnes, Matthias Schieker, Eckhard Weber filed Critical Novartis Ag
Publication of IL316872A publication Critical patent/IL316872A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL316872A 2022-05-18 2023-05-18 Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists IL316872A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263343510P 2022-05-18 2022-05-18
PCT/IB2023/055138 WO2023223263A1 (en) 2022-05-18 2023-05-18 Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Publications (1)

Publication Number Publication Date
IL316872A true IL316872A (en) 2025-01-01

Family

ID=87060105

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316872A IL316872A (en) 2022-05-18 2023-05-18 Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Country Status (8)

Country Link
EP (1) EP4525914A1 (en)
JP (1) JP2025516723A (en)
KR (1) KR20250011948A (en)
CN (1) CN119546340A (en)
AU (1) AU2023270497A1 (en)
CA (1) CA3257386A1 (en)
IL (1) IL316872A (en)
WO (1) WO2023223263A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL447022A1 (en) * 2023-12-07 2025-06-09 Wasilczyk Cezary Pharmaceutical composition for use in the treatment and regeneration of the locomotor system, pharmaceutical composition and method of treatment using the composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (en) 2005-12-13 2021-02-08 Eli Lilly And Company Anti-il-17 antibodies
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
BRPI0908312A2 (en) 2008-05-05 2015-08-18 Novimmune Sa '' Isolated fully human monoclonal antibody, pharmaceutical composition, symptom-relieving method of a clinical indication, and method of relieving a symptom of an autoimmune disease, inflammatory disorder or cell proliferation disorder ''
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
AR091116A1 (en) 2012-05-22 2015-01-14 Bristol Myers Squibb Co BISPECIFIC ANTIBODIES AND THEIR METHODS OF USE
LT2953969T (en) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP3027649B1 (en) 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
CN107148283A (en) 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 Anti-IL-17A and IL-17F cross-reactive antibody variants, compositions comprising the same, and methods of making and using the same
AU2018361975A1 (en) * 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists

Also Published As

Publication number Publication date
CA3257386A1 (en) 2023-11-23
KR20250011948A (en) 2025-01-22
JP2025516723A (en) 2025-05-30
WO2023223263A1 (en) 2023-11-23
EP4525914A1 (en) 2025-03-26
CN119546340A (en) 2025-02-28
AU2023270497A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
PT4303583T (en) Methods of treating disorders using csf1r inhibitors cross-reference to related applications
JO3559B1 (en) An antibody FOR TREATING OR PREVENTING MIGRAINE HEADACHE AND METHOD OF THEREOF USE
MX2022008255A (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MY184189A (en) Methods of treating nail and scalp psoriasis
IL257723A (en) Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
EA202193345A1 (en) ANTIBODIES TO NATRIURETIC PEPTIDE RECEPTOR-1 AND METHODS FOR THEIR APPLICATION
EA201890567A1 (en) CANCER TREATMENT METHOD
AU2022233762A1 (en) Method of treating diseases using gremlin1 antagonists
ZA202206163B (en) Methods of treating coronavirus
HK1247562A1 (en) Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
MX2021008716A (en) Method for treating osteoarthritis pain by administering resiniferatoxin.
IL274214A (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
IL299339A (en) Antibodies and methods for treating claudin-associated diseases
IL318512A (en) Methods for the treatment of hypertension via transcranial-focused-ultrasound
IT201900020274A1 (en) TIP FOR SURGERY AND METHOD OF IMPLEMENTATION
EA202092125A1 (en) ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION
AR116668A1 (en) AGONIST ANTIBODIES AGAINST CD200R AND ITS USES
MX2024001954A (en) Il-13 antibodies for the treatment of atopic dermatitis.
IL325649A (en) Method of treating depression using seltorexant
WO2017140684A3 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
IL288003A (en) Methods of treating cancer using chk1 inhibitors
HUE069670T2 (en) Composition and method for treatment of multiple sclerosis
HK40026039A (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists